Bio-Rad Laboratories, Inc. (BIO)
After hours:
| Previous close | 279.73 |
| Open | 281.73 |
| Bid | 0.00 x 1200 |
| Ask | 0.00 x 3000 |
| Day's range | 277.71 - 283.42 |
| 52-week range | 261.59 - 473.50 |
| Volume | |
| Avg. volume | 209,775 |
| Market cap | 7.988B |
| Beta (5Y monthly) | 0.88 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Bio-Rad to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
HERCULES, Calif., April 18, 2024--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the first quarter of 2024 on Tuesday, May 7, 2024, following the close of the market. Management will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.
- GlobeNewswire
Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay
- Bio-Rad expects to make equity investment in support of deal - Agreement provides for global exclusivity in transplant monitoring commercialization - Bio-Rad granted subsequent investment option upon FDA clearance IRVINE, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced a partnership agreement with Bio-Rad Laboratories (NYSE: BIO), a global leader in life science research and clinical diagnostics products, for the c
- Business Wire
Bio-Rad’s Chief Operating Officer Andrew Last to Retire
HERCULES, Calif., April 10, 2024--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that Dr. Andrew Last, Executive Vice President and Chief Operating Officer, is planning to retire by early September of 2024. Dr. Last will remain part of Bio-Rad’s executive leadership team to ensure a smooth transition while the company conducts a search for his successor.
